Abeona Therapeutics Appoints Edward Carr as Main Fiscal Officer
NEW YORK and CLEVELAND, Aug. 10, 2021 (Globe NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-built-in chief in gene and mobile therapy, nowadays declared the appointment of Edward Carr as Main Money Officer and Principal Money Officer, helpful promptly. Mr. Carr experienced served as Abeona’s Chief Accounting Officer because January 2019.
“I look ahead to operating collectively with Ed to fulfill our near-expression clinical and regulatory milestones, as nicely as established Abeona on a training course for for a longer time-time period success for patients and shareholders,” reported Michael Amoroso, Main Govt Officer of Abeona. “Ed’s money management and deep comprehending of our company assists place Abeona for even further accomplishment as we continue to execute on our strategic and money priorities centered on price-extra expansion.”
Mr. Carr joined the Firm in November 2018 as Corporate Controller, bringing extra than 25 many years of economic management knowledge serving in numerous finance roles of escalating obligation. He has broad and considerable expertise running accounting, monetary reporting, inner controls, tax and treasury matters. Prior to becoming a member of Abeona, Mr. Carr served as Assistant Controller at Coty Inc., a multi-billion dollar, publicly traded producing organization and as Chief Accounting Officer at Foster Wheeler AG, a multi-billion dollar, publicly traded engineering and construction firm. Mr. Carr, who is a Qualified Public Accountant, started his career at Ernst & Younger LLP. He retains B.S. and Master of Expert Accountancy degrees from West Virginia University.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a scientific-phase biopharmaceutical corporation building gene and cell therapies for critical conditions. Abeona’s clinical courses include EB-101, its investigational autologous, gene-corrected cell remedy for recessive dystrophic epidermolysis bullosa in Stage 3 growth, as effectively as ABO-102 and ABO-101, novel investigational AAV-primarily based gene therapies for Sanfilippo syndrome sorts A and B (MPS IIIA and MPS IIIB), respectively, in Section 1/2 progress. The Company’s growth portfolio also capabilities AAV-primarily based gene therapies for ophthalmic ailments with significant unmet health care will need. Abeona’s novel, future-generation AAV capsids are remaining evaluated to increase tropism profiles for a variety of devastating diseases. Abeona’s absolutely integrated gene and mobile therapy cGMP producing facility makes EB-101 for the pivotal Period 3 VIITAL™ review and is capable of scientific and prepared commercial output of AAV-based gene therapies. For more info, stop by www.abeonatherapeutics.com.
Ahead-Wanting Statements
This press launch incorporates specific statements that are ahead-wanting inside the meaning of Segment 27A of the Securities Act of 1933, as amended, and Portion 21E of the Securities Exchange Act of 1934, as amended, and that involve threats and uncertainties. We have attempted to establish ahead-on the lookout statements by these kinds of terminology as “may,” “will,” “believe,” “estimate,” “expect,” and identical expressions (as perfectly as other phrases or expressions referencing long term events, circumstances or circumstances), which constitute and are meant to identify forward-searching statements. Genuine results may possibly differ materially from individuals indicated by this kind of forward-hunting statements as a outcome of different essential variables, numerous pitfalls and uncertainties, together with but not confined to the probable impacts of the COVID-19 pandemic on our business enterprise, operations, and economic condition, continued curiosity in our exceptional illness portfolio, our skill to enroll clients in scientific trials, the consequence of any foreseeable future conferences with the U.S. Meals and Drug Administration or other regulatory companies, the affect of competitors, the means to protected licenses for any know-how that may perhaps be required to commercialize our products, the capability to accomplish or receive important regulatory approvals, the impression of improvements in the monetary markets and international financial problems, challenges connected with knowledge analysis and reporting, and other pitfalls disclosed in the Company’s most modern Annual Report on Type 10-K and subsequent quarterly stories on Variety 10-Q and other periodic reviews submitted with the Securities and Exchange Commission. The Organization undertakes no obligation to revise the forward-looking statements or to update them to replicate activities or conditions taking place immediately after the date of this push release, whether as a outcome of new facts, upcoming developments or normally, apart from as required by the federal securities guidelines.
Contact: Investor and Media Get hold of: Greg Gin VP, Trader Relations and Corporate Communications Abeona Therapeutics +1 (646) 813-4709 [email protected]
